Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN2176-3 · 1 trial · 1 indication
The primary endpoint in the study is the incidence of treatment emergent adverse events (TEAEs) from day 1 through week 24 in patients treated with IVT REGN2176-3.
| Arm | Type | Description |
|---|---|---|
| Cohorts 1 - 4 | EXPERIMENTAL | Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4. |
| Name | Type | Description |
|---|---|---|
| REGN2176-3 | DRUG | - |
Inclusion Criteria: Key Criteria: Men or women greater than or equal to 50 years of age who provide informed consent and have active subfoveal choroidal neovascularization (CNV) secondary to wet AMD. Exclusion Criteria: 1. Any prior treatment with an inhibitor of PDGF (platelet-derived growth fa...
REGN2176-3 is an investigational small molecule developed by Regeneron Pharmaceuticals for neovascular wet age-related macular degeneration, also known as wet AMD. It was studied as an intravitreal injection in a Phase 1 safety trial in patients aged 50 years and older. It is not an approved therapy.
REGN2176-3 was evaluated for the treatment of neovascular wet age-related macular degeneration, a form of AMD marked by abnormal blood vessel growth under the retina. The clinical program studied it in patients aged 50 years and older with wet AMD. It remains investigational and is not approved for any use.
REGN2176-3 targets PDGFR-beta, a protein receptor. PDGFR-beta is a platelet-derived growth factor receptor that supports the survival and recruitment of cells forming new blood vessels, a process relevant to the vascular pathology of wet AMD. REGN2176-3 is a small molecule directed at this target.
REGN2176-3 is being developed by Regeneron Pharmaceuticals, Inc., which trades on Nasdaq under the ticker REGN. Regeneron sponsored the Phase 1 safety study of the compound in patients with wet age-related macular degeneration conducted in the United States.
REGN2176-3 is in Phase 1 development. Its only recorded clinical trial, NCT02061865, was a Phase 1 safety study in patients aged 50 years and older with wet AMD. That trial is completed, and REGN2176-3 is investigational rather than an approved treatment.
REGN2176-3 has been studied in one clinical trial, NCT02061865, titled a Phase 1 safety study with intravitreal REGN2176-3 in patients aged 50 years and older with wet AMD. The trial enrolled 12 patients in the United States, was uncontrolled, and is now completed.